# A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

> **NCT02349295** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 363 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ixekizumab 80 mg Q4W
- **DRUG:** Ixekizumab 80 mg Q2W

## Key facts

- **NCT ID:** NCT02349295
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-31
- **Primary completion:** 2016-09-09
- **Final completion:** 2019-06-26
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349295, "A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02349295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*